TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy.
Acta Biomater
; 143: 392-405, 2022 04 15.
Article
in En
| MEDLINE
| ID: mdl-35259519
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Nanoparticles
/
Triple Negative Breast Neoplasms
Type of study:
Prognostic_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Acta Biomater
Year:
2022
Document type:
Article
Affiliation country:
China